Multi Bintang Indonesia Tbk. vs Prodia Diagnostic Line Tbk — how do they compare? Multi Bintang Indonesia Tbk. trades at Rp6,975 (market cap 14.85T, 42.2K 24h volume), while Prodia Diagnostic Line Tbk trades at Rp270 (market cap 470.58B, 28.43M 24h volume). The key difference: Multi Bintang Indonesia Tbk. is far larger — about 31.6× Prodia Diagnostic Line Tbk's market cap, and Prodia Diagnostic Line Tbk is more actively traded (28.43M versus 42.2K). Which is the better fit depends on your goals.
| MLBI | PRDL | |
|---|---|---|
Market Cap | 14.85T | 470.58B |
Volume | 42.2K | 28.43M |
Lot | 422 | 284.34K |
Turnover | 293.55M | 7.8B |
Average Price | 6,956.22 | 274.19 |
Value | 293.55M | 7.8B |
Indicative Equilibrium Price | 6,975 | 270 |
Indicative Equilibrium Volume | 1 | 2.1K |
Trailing returns across standard periods
Latest headlines on both assets
PT Multi Bintang Indonesia Tbk (The Company) was established on June 3, 1929, based on notarial deed No. 8 of Tjeerd Dijkstra, notary public in Medan, under the name of NV Nederlandsch Indische Bierbrouwerijen. The Company is part of the Heineken Group, where the ultimate shareholder is Heineken N.V. (Heineken).
Read more on MLBI →PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →